|
Incidence and relative hazard of primary outcome by genotype |
|||||||||
| Gene |
Genotype |
No. Events (%) |
Primary Outcome Incidence* |
All Patients Adjusted HR (95%CI)† n = 628 |
P |
Whites Adjusted HR (95%CI)† n = 524 |
P |
Blacks Adjusted HR (95%CI)† n = 104 |
P |
|
|
|||||||||
| ADRB1 |
|||||||||
| Ser49Gly |
Ser/Ser |
82 (18) |
4.2 |
1.00 (reference) |
1.00 (reference) |
1.00 (reference) |
|||
| Ser/Gly |
30 (18) |
3.8 |
0.88 (0.57–1.37) |
0.58 |
0.89 (0.51–1.53) |
0.66 |
1.12 (0.51–2.48) |
0.78 |
|
| Gly/Gly |
3 (33) |
6.4 |
1.02 (0.31–3.36) |
0.98 |
... |
0.98 |
1.95 (0.47–8.03) |
0.36 |
|
| Arg389Gly |
Arg/Arg |
44 (15) |
3.2 |
1.00 (reference) |
1.00 (reference) |
1.00 (reference) |
|||
| Arg/Gly |
55 (20) |
4.5 |
1.15 (0.77–1.71) |
0.49 |
1.09 (0.69–1.72) |
0.71 |
1.23 (0.56–2.83) |
0.62 |
|
| Gly/Gly |
14 (26) |
7.2 |
1.94 (1.05–3.59) |
0.03 |
1.82 (0.92–3.61) |
0.09 |
2.27 (0.53–9.79) |
0.27 |
|
| ADRB2 |
|||||||||
| Gly16Arg |
Gly/Gly |
34 (18) |
4.0 |
1.00 (reference) |
1.00 (reference) |
1.00 (reference) |
|||
| Gly/Arg |
57 (18) |
4.0 |
0.93 (0.60–1.43) |
0.73 |
0.90 (0.56–1.46) |
0.67 |
1.09 (0.38–3.19) |
0.87 |
|
| Arg/Arg |
24 (21) |
4.6 |
1.14 (0.67–1.93) |
0.63 |
0.81 (0.42–1.57) |
0.53 |
2.61 (0.81–8.42) |
0.11 |
|
| Gln27Glu |
Gln/Gln |
52 (20) |
4.4 |
1.00 (reference) |
|||||
| Gln/Glu |
49 (17) |
3.8 |
0.88 (0.59–1.30) |
0.51 |
1.06 (0.67–1.71) |
0.79 |
0.51 (0.20–1.30) |
0.16 |
|
| Glu/Glu |
14 (18) |
4.4 |
0.99 (0.53–1.84) |
0.98 |
1.13 (0.59–2.15) |
0.72 |
... |
0.99 |
|
| ADRB3‡ |
|||||||||
| Trp64Arg |
Trp/Trp |
93 (18) |
4.0 |
1.00 (reference) |
1.00 (reference) |
1.00 (reference) |
|||
| Trp/Arg + Arg/Arg |
21 (20) |
4.8 |
1.32 (0.81–2.14) |
0.26 |
1.19 (0.67–2.14) |
0.55 |
1.33 (0.51–3.50) |
0.56 |
|
| ADRA1A |
|||||||||
| Arg347Cys |
Arg/Arg |
31 (18) |
4.1 |
1.00 (reference) |
1.00 (reference) |
1.00 (reference) |
|||
| Arg/Cys |
58 (19) |
4.4 |
1.03 (0.66–1.62) |
0.88 |
0.97 (0.60–1.57) |
0.89 |
1.05 (0.20–5.43) |
0.95 |
|
| Cys/Cys |
26 (18) |
3.5 |
0.68 (0.37–1.18) |
0.16 |
0.83 (0.43–1.58) |
0.56 |
0.46 (0.08–2.39) |
0.35 |
|
| GNAS |
|||||||||
| 393 T > C |
T/T |
36 (18) |
3.9 |
1.00 (reference) |
1.00 (reference) |
1.00 (reference) |
|||
| T/C |
58 (20) |
4.5 |
1.10 (0.71–1.69) |
0.67 |
1.26 (0.73–2.17) |
0.40 |
0.97 (0.39–1.93) |
0.74 |
|
| C/C |
21 (16) |
3.6 |
1.31 (0.74–2.31) |
0.36 |
1.60 (0.85–3.01) |
0.15 |
... |
0.99 |
|
| GNB3 |
|||||||||
| 825 C > T |
C/C |
47 (16) |
3.7 |
1.00 (reference) |
1.00 (reference) |
1.00 (reference) |
|||
| C/T |
42 (18) |
3.8 |
1.06 (0.69–1.64) |
0.78 |
1.26 (0.73–2.17) |
0.40 |
0.87 (0.40–1.93) |
0.74 |
|
| T/T |
26 (26) |
6.1 |
1.51 (0.82–2.77) |
0.19 |
1.60 (0.85–3.01) |
0.15 |
... |
0.99 |
|
|
Abbreviations: HR, hazard ratio; 95%CI, 95% confidence interval * incidence per 100 patient-years † adjusted for age, race, presence of obstructive CAD, history of diabetes, ever-smoking, baseline systolic BP, BMI ‡ analyzed using dominant model based on minor allele frequency ≤ 0.1 | |||||||||
Pacanowski et al. Journal of Translational Medicine 2008 6:11 doi:10.1186/1479-5876-6-11 |
|||||||||